Q-Line Biotech Limited

Other expenses increased by 33.20% from ₹ 3688.99 lakhs in Fiscal 2023 to ₹ 4913.78 lakhs in Fiscal 2024. The main reason for increase in the other expenses is the decrease in the manufacturing expenses of the company which has increased to 2740.90 from 1598.37 in the financials year 23.

## Tax Expenses

Current tax increased by 5.94% from ₹ 845.76 lakhs in Fiscal 2023 to ₹ 895.96 lakhs in Fiscal 2023. Such increase is the resulting factor of decreased profits.

## Profit after Tax

The profit after tax of the company increased from ₹ 3209.71 lakhs in the Fiscal 2023 to ₹ 3444.92 lakhs in the Fiscal 2024 representing an increase of 7.33%, however on Pat level we have seen the negative growth from 17.37% to 16.69%. The decrease in the PAT margin was the resultant of the increase in expenses of the company which increased from 83.85% to 85.18% in the financial year 2024. The decrease in the profits is also on account of increased finance cost, Depreciation expenses and increased other expenses. Reasons for these are explained as above.

## Information required as per Item (II)(C)(iv) of Part A of Schedule VI to the SEBI Regulations:

An analysis of reasons for the changes in significant items of income and expenditure is given hereunder:

1. **Unusual or infrequent events or transactions**

There has not been any unusual trend on account of our business activity. Except as disclosed in this Draft Red Herring Prospectus, there are no unusual or infrequent events or transactions in our Company.

2. **Significant economic changes that materially affected or are likely to affect income from continuing operations.**

There are no significant economic changes that may materially affect or likely to affect income from continuing operations.

3. **Known trends or uncertainties that have had or are expected to have a material adverse impact on sales, revenue or income from continuing operations.**

Apart from the risks as disclosed under Section "Risk Factors" beginning on page 29 of the Draft Red Herring Prospectus, in our opinion there are no other known trends or uncertainties that have had or are expected to have a material adverse impact on revenue or income from continuing operations.

4. **Future changes in relationship between costs and revenues**

Other than as described in the sections "Risk Factors", "Our Business" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" on pages 29, 123 and 246 respectively, to our knowledge, no future relationship between expenditure and income is expected to have a material adverse impact on our operations and finances.

5. **Segment Reporting**

Our business activity primarily falls within a single business and geographical segment, other than as disclosed in "Restated Financial Statements" on page 179 we do not follow any other segment reporting

6. **Status of any publicly announced New Products or Business Segment**

Except as disclosed in the Chapter "Our Business", our Company has not announced any new product or service.

7. **Seasonality of business**

Our business and revenue from operations are not subject to seasonality. For further information, see "Industry Overview" and "Our Business" on pages 103 and 123, respectively of this Draft Red Herring Prospectus.

8. **Dependence on single or few customers**

Given the nature of our business operations, we have dependency on few customers, our top two customers contributed 68.19% of the total revenue for the year ended March 31, 2025. Further, the concentration of our revenue is depended on our top customers. In